Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand

Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(17min)CommentsSummaryVertex Pharmaceuticals (VRTX) remains a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA.VRTX's new label expansions now cover 95% of U.S. CF patients, adding 800 eligible patients and supporting continued revenue growth.Positive phase 3 data for povetacicept in IgAN and ongoing regulatory submissions position VRTX for further diversification beyond CF.Guidance for 2026 targets $12.95–$13.1 billion in total revenue, with non-CF products expected to contribute over $500 million.Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Olga Yastremska/iStock via Getty Images The last time I spoke about Vertex Pharmaceuticals (VRTX) it was with a Seeking Alpha article entitled "Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy." With respect to this article, I mentioned that theThis article was written byTerry Chrisomalis14.81K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.